| |
Ascertained COVID (n = 9)
|
Non COVID (n = 287)
|
p value
|
|---|
|
General (n = 296)
|
|
Age years-old, mean (SD)
|
46.22 (9.55)
|
53.15 (17.78)
|
0.25
|
|
Range
|
35–65
|
3–86
| |
|
Gender (female), n (%)
|
3 (33.3)
|
154
|
0.31
|
|
Clinical, HHT-related (n = 296)a
|
|
Epistaxis, n (%)
|
9/9 (100)
|
274/287 (95.5)
|
1
|
|
PAVMs, n (%)
|
2/9 (22.2)
|
98/270 (36.3)
|
0.5
|
|
BAVMs, n (%)
|
0
|
27/226 (11.9)
|
0.4
|
|
HAVMs, n (%)
|
2/9 (22.2)
|
102/266 (38.3)
|
1
|
|
GI bleeding, n (%)
|
1/9 (11.1)
|
51/287 (17.8)
|
1
|
|
Mutated gene (n = 296)
|
|
Identified Mutation, n (%)
|
9 (100)
|
227 (79.1)
|
0.13
|
|
ENG
|
3 (33.3)
|
83 (29)
| |
|
ALK1/ACVRL1
|
6 (66.7)
|
143 (49.8)
| |
|
SMAD4
|
0
|
1 (0.3)
| |
|
Mutation unidentified/Ongoing analysis, n (%)
|
0
|
60 (20.9)
| |
- aThe presence of HHT-related visceral arterio-venous malformations was computed by considering only those patients with screening performed in each given organ
- BAVMs brain arterio-venous malformations, HAVMs hepatic arterio-venous malformations, PAVMs pulmonary arterio-venous malformations
